[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606852":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":40,"locations":46,"responsibleParty":61,"collaborators":31,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":31,"eligibilityCriteria":68,"healthyVolunteers":65,"sex":69,"minAge":70,"maxAge":31,"enrollmentInfo":71,"targetDuration":31,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":31,"overallStatus":48,"whyStopped":31,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Poznan University of Medical Sciences","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Control group","PLACEBO_COMPARATOR","Bilateral ESPB (2 x 20ml 0.2% ropivacaine with 1ml 0.9% NaCl)",[13],"Drug: 0.9%NaCl",{"label":15,"type":16,"description":17,"interventionNames":18},"Dexamethasone group","EXPERIMENTAL","Bilateral ESPB (2 x 20ml 0.2% ropivacaine with 2mg dexamethasone)",[19],"Drug: Dexamethasone 4mg",{"label":21,"type":16,"description":22,"interventionNames":23},"Dexmedetomidine group","Bilateral ESPB (2 x 20ml 0.2% ropivacaine with 25ug dexmedetomidine)",[24],"Drug: Dexmedetomidine",[26,32,36],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","0.9%NaCl","2 x 20ml 0.2% ropivacaine with 2ml of 0.9% NaCl",[9],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Dexamethasone 4mg","2 x 20ml 0.2% ropivacaine with 2mg of dexamethasone",[15],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"Dexmedetomidine","2 x 20ml 0.2% ropivacaine with 25ug Dexmedetomidine",[21],[41],{"name":42,"role":43,"phone":44,"phoneExt":31,"email":45},"Malgorzata Reysner, M.D. Ph.D.","CONTACT","+48 61 873 83 03","mreysner@ump.edu.pl",[47],{"facility":5,"status":48,"city":49,"state":31,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Poznan","62-701","Poland","PL",{"type":54,"coordinates":55},"Point",[56,57],16.92993,52.40692,{"lat":57,"lon":56},[60],{"name":42,"role":43,"phone":44,"phoneExt":31,"email":45},{"type":62,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100606852","phase-4-comparison-of-perineural-dexamethasone-versus-dexmedetomidine-as-adjuvants-to-erector-spinae-plane-block-in-lumbar-spine-surgery-a-randomized-double-blind-controlled-trial-100606852",false,"NCT07180940","Comparison of Perineural Dexamethasone Versus Dexmedetomidine as Adjuvants to Erector Spinae Plane Block in Lumbar Spine Surgery: A Randomized, Double-blind, Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 to N\u002FA (no limit)\n* Scheduled for elective lumbar spine surgery (e.g., decompression or fusion) via posterior approach\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Body weight ≥ 50 kg\n* Ability to provide written informed consent\n* Expected postoperative hospitalization of at least 48 hours\n\nExclusion Criteria:\n\n* Known allergy or contraindication to ropivacaine, dexamethasone, or dexmedetomidine\n* Infection at or near the site of block placement\n* Coagulation disorders or current use of anticoagulant therapy (not discontinued per guidelines)\n* Chronic opioid use or opioid dependence\n* Neurological or psychiatric disorders interfering with pain assessment\n* Diabetes mellitus with poorly controlled glycemia (e.g., HbA1c \\> 8%)\n* Severe hepatic or renal dysfunction\n* Body mass index (BMI) \\> 40 kg\u002Fm²\n* Pregnancy or breastfeeding\n* Refusal or inability to cooperate with the study protocol","ALL","18 Years",{"count":72,"type":73},150,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","This clinical study aims to determine which of two medications-dexamethasone or dexmedetomidine-works better and is safer when used together with a local anesthetic (ropivacaine) in a type of nerve block called the erector spinae plane block (ESPB). This block helps reduce pain after lumbar spine surgery.",[79,80],"Spine Disease","Spinal Diseases","2025-09-12",{"date":83,"type":84},"2025-09-18","ACTUAL",{"date":86,"type":84},"2025-09-01",{"date":88,"type":73},"2026-12-31",{"name":5,"class":6},1]